ERV2 Stock Overview
Engages in production and co-packing of cannabis-infused beverages in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Molecule Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.0005 |
| 52 Week High | CA$0.02 |
| 52 Week Low | CA$0.0005 |
| Beta | -0.78 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -92.86% |
| 33 Year Change | -99.26% |
| 5 Year Change | n/a |
| Change since IPO | -98.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| ERV2 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.0% | 1.0% |
| 1Y | -92.9% | -15.0% | 11.2% |
Return vs Industry: ERV2 underperformed the German Pharmaceuticals industry which returned -19.5% over the past year.
Return vs Market: ERV2 underperformed the German Market which returned 3.2% over the past year.
Price Volatility
| ERV2 volatility | |
|---|---|
| ERV2 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ERV2 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ERV2's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | David Reingold | molecule.ca |
Molecule Holdings Inc. engages in production and co-packing of cannabis-infused beverages in Canada. It also offers cannabis extracts, beverages, edibles, and topical products directly to provincial retailers. The company offers its beverage products under the PHRESH, KLÕN, EMBODY, and CANAJO brands.
Molecule Holdings Inc. Fundamentals Summary
| ERV2 fundamental statistics | |
|---|---|
| Market cap | €330.75k |
| Earnings (TTM) | -€3.45m |
| Revenue (TTM) | €1.78m |
0.0x
P/S Ratio0.0x
P/E RatioIs ERV2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ERV2 income statement (TTM) | |
|---|---|
| Revenue | CA$1.78m |
| Cost of Revenue | CA$2.23m |
| Gross Profit | -CA$449.70k |
| Other Expenses | CA$3.01m |
| Earnings | -CA$3.45m |
Last Reported Earnings
Jul 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.035 |
| Gross Margin | -25.27% |
| Net Profit Margin | -194.18% |
| Debt/Equity Ratio | -102.3% |
How did ERV2 perform over the long term?
See historical performance and comparison